Agonist Prodrug For The Treatment Of Obesity
16/06/2025 13:04
June 16 (Reuters) - MBX Biosciences Inc MBX.O: MBX BIOSCIENCES ANNOUNCES IND SUBMISSION OF MBX 4291, ITS LONG-ACTING GLP1/GIP RECEPTOR CO-AGONIST PRODRUG FOR THE TREATMENT OF OBESITY MBX BIOSCIENCES INC - PHASE 1 TRIAL OF MBX 4291 EXPECTED TO INITIATE IN Q3 2025 Source text: ID:nGNX6vJrXw Further company coverage: MBX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MBX Biosciences
See all newsU.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC Solutions
MBX Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: MBX Biosciences Announces Executive Leadership Transition To Support The Company’S Next Phase Of Growth
MBX Biosciences falls after executive shakeup
U.S. STOCKS ON THE MOVE-SpaceX, Tesla, Woodside Energy Group